Additionally, the levels of soluble BCMA were inversely correlated with the percentage of mBCMA+ CD19+ B cells in SLE patients (rs = −0.4237, p < 0.05) (Fig. 1H). This evidence concerns the gene CD19 and systemic lupus erythematosus.